Information on Breast Implants and ALCL(Anaplastic Large Cell Lymphoma)
"In 2011, the FDA identified a possible association between breast implants and the development of anaplastic large cell lymphoma (ALCL), a rare type of non-Hodgkin’s lymphoma. At that time, the Agency was aware of approximately 60 cases of ALCL in women with breast implants, out of approximately 5-10 million women who had received breast implants worldwide. This included 34 unique cases that were described in the medical literature from January 1, 1997 through May 21, 2010, and additional cases identified by international regulatory agencies, scientific experts and breast implant manufacturers. Based on this data, the FDA cautioned patients and health care providers that women with breast implants might have a very low but increased risk of developing ALCL.
The FDA also posted on this website a detailed analysis of the 34 cases of ALCL in women with breast implants, provided physicians with interim recommendations on identifying and confirming ALCL, and worked with breast implant manufacturers to include information regarding ALCL in the patient and physician labeling.
Because the FDA knew of so few cases of this disease, it was impossible to determine what factors increased the risk. In a report summarizing the Agency’s findings, we emphasized the need to gather additional information to better characterize ALCL in women with breast implants." - From FDA information on Breast Implant and ALCL
For more information Please click on one of the links below:
FDA information on Breast Implant and ALCL
American Society of Plastic Surgeons
National Institute of Health